Enantiomerically pure hydroxylated xanthine compounds
AssigneeCell Therapeutics, Inc.
InventorsJames A. Bianco, Paul Woodson, David Porubek, Jack Singer
Life of this patent
Estimating the term…
Abstract
There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.
Claims12
A method for treating or preventing infection following treatment for a hematologic malignancy, comprising administering a compound of formula I, or a pharmaceutical composition thereof, to a patient receiving treatment for said hematologic malignancy, formula I being represented by:
- ##STR9## wherein R.sub.1 is substantially an R enantiomer .omega.-1 secondary alcohol-substituted C.sub.5-8 alkyl wherein R.sub.2 is C.sub.1-12 alkyl, optionally containing one or two nonadjacent oxygen atoms in place of a carbon atom, and R.sub.3 is CH.sub.3 or H.
A method for treating or preventing hematocytopenia following administration of therapies to treat hematologic malignancies, comprising administering a compound of formula I, or a pharmaceutical composition thereof, formula I being represented by:
- ##STR10## wherein R.sub.1 is substantially an R enantiomer .omega.-1 secondary alcohol-substituted C.sub.5-8 alkyl wherein R.sub.2 is C.sub.1-12 alkyl, optionally containing one or two nonadjacent oxygen atoms in place of a carbon atom, and R.sub.3 is CH.sub.3 or H.
Dependencies are inferred from the claim text.